← Back to Search

Virus Therapy

Single Influenza Vaccine for Cellular Immunity

Phase < 1
Waitlist Available
Led By Ali Ellebedy, PhD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 and day 28
Awards & highlights

Study Summary

This study is evaluating whether a vaccine can be used to collect blood samples and lymph node cells.

Eligible Conditions
  • Cellular Immunity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 and day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine the percentage of subjects achieving seroconversion
Secondary outcome measures
Determine the frequency of vaccine-induced responses

Side effects data

From 2015 Phase 4 trial • 985 Patients • NCT02290691
64%
Tenderness
48%
Pain
35%
Redness
29%
Swelling
24%
Itching
20%
Muscle Ache
15%
Headache
12%
Fatigue
10%
Bruising
5%
Chills
4%
Nausea
1%
Vomiting
1%
Fever
100%
80%
60%
40%
20%
0%
Study treatment Arm
Needle- Free
Needle and Syringe

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single Influenza VaccineExperimental Treatment1 Intervention
Single Influenza Vaccine,Quadrivalent
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Influenza Vaccine
2010
Completed Phase 4
~6900

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,935 Previous Clinical Trials
2,299,862 Total Patients Enrolled
Ali Ellebedy, PhDPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine
2018. "Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03748524.
All > Influenza
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top